Clinical and Regulatory Affairs Expert Pamela
Misajon Brings Drug-Development Expertise
Finance and Technology Executive Michael Catlin
to Chair the Audit Committee
Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the
“Company”), a clinical-stage, fully-integrated biotherapeutics
company using its proprietary DIAMOND® artificial intelligence and
data mining platform to develop cell therapies with a focus on
immuno-oncology, announces the appointments of Pamela Misajon and
Michael Catlin to its Board of Directors. Their regulatory and
finance experience enhances Kiromic’s governance and re-establishes
the Company’s five-member Board of Directors.
“We are delighted to welcome Pam and Michael to Kiromic’s Board.
Pam’s impressive biopharmaceutical experience, including expertise
with U.S. and international regulatory strategies, will play a
valuable role in advancing our Deltacel program through the clinic.
We are confident that her strategic insight and leadership skills
will contribute to guiding our development pathway, beginning with
non-small cell lung cancer,” stated Michael Nagel, Chairperson of
Kiromic’s Board of Directors. “With Michael’s exceptional
proficiency in IT and finance, along with his passion for
leveraging technology to drive innovation, his appointment aligns
with our vision for using our proprietary DIAMOND® AI-powered
analysis to continue identifying and developing potential cell
therapies to address solid tumor cancers.”
"I am honored to join the Board of Directors at Kiromic
Biopharma, a company that is at the forefront of pioneering
personalized solid tumor cancer treatments, an area of significant
unmet need. I am inspired by the team's dedication to improving
patient outcomes through innovative science, and I look forward to
contributing my experience and insight to accelerate the
development of Kiromic’s Deltacel program," said Ms. Misajon.
"I am passionate about leveraging technology and data-driven
approaches to drive innovation in cancer treatments. I look forward
to joining the Kiromic Board and contributing to their
groundbreaking efforts in precision medicine. As Chair of the Audit
Committee and with a keen understanding of the capital markets, I
intend to be a resource in responsibly guiding invested capital,"
said Mr. Catlin.
About Pamela Misajon
Pam Misajon brings to Kiromic more than three decades of
experience with a comprehensive background in drug development,
regulatory affairs and clinical operations, as well as product
commercialization strategies. She has held several high-profile
positions within the biopharmaceutical industry, including
currently serving as Chief Compliance Officer and Vice President of
Operations, Regulatory and Quality Affairs at Suneva Medical.
Prior to Suneva Medical, Ms. Misajon held positions at several
pharmaceutical companies, including Vice President of Regulatory
Affairs at Neomend, where she played a key role in securing
regulatory approvals for multiple breakthrough therapies. She also
held executive regulatory and clinical affairs positions at Ellipse
Technologies, Pegasus Biologics, and IntraLuminal Therapeutics.
Ms. Misajon received a B.A. in Business Management from the
University of Phoenix, San Diego Campus.
About Michael Catlin
As Senior Vice President, Chief Information Security Officer,
and Head of Technology Services at Capital Group from 1994 to 2022,
Mr. Catlin played a pivotal role in transforming the organization's
approach to security. He modernized and expanded the company’s
security program, evolving IT to a top business priority. He also
had a significant impact on technology infrastructure at Capital
Group, overseeing 500 global associates and a $400 million annual
budget. His initiatives resulted in improved system availability
and streamlined operations to support business growth and effective
cost control.
Mr. Catlin serves on Capital Group’s audit committee, the
operations risk oversight committee, the information security
steering committee, and the American Funds Service board. He is
also Chair of the Investment Company Institute.
Mr. Catlin received a B.S. in Business Computer Methods and an
M.S. in Computer Science from California State University.
About Kiromic BioPharma
Kiromic BioPharma, Inc. is a clinical-stage, fully integrated
biotherapeutics company using its proprietary DIAMOND® artificial
intelligence (AI) 2.0 target discovery engine to develop and
commercialize cell therapies focusing on immuno-oncology. Kiromic
is developing a multi-indication allogeneic cell therapy platform
that exploits the natural potency of Gamma Delta T-cells to target
solid cancers. Kiromic’s DIAMOND® AI is where data science meets
target identification to dramatically compress the years and
hundreds of millions of dollars required to develop a live drug.
The Company maintains offices in Houston, Texas. To learn more,
visit www.kiromic.com and connect with us on Twitter and
LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. Kiromic makes such
forward-looking statements pursuant to the safe harbor provisions
of the United States Private Securities Litigation Reform Act,
Section 21E of the Securities Exchange Act of 1934, as amended, and
other federal securities laws. All statements other than statements
of historical facts are forward-looking statements. In some cases,
you can identify forward-looking statements by terms such as:
“will,” “potential,” “could,” “can,” “believe,” “intends,”
“continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,”
or the negative of these terms or other comparable terminology.
These forward-looking statements include, but are not limited to,
statements regarding: Kiromic’s ability to achieve its objectives
and Kiromic’s financing strategy and availability of funds. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
levels of activity, performance, or achievements to be materially
different from the information expressed or implied expressed or
implied by these forward-looking statements. These risks and
uncertainties include, but are not limited to, the risks and
uncertainties discussed in our Annual Report on Form 10-K for the
year ended December 31, 2022, and as detailed from time to time in
our other SEC filings. You should not rely upon forward-looking
statements as predictions of future events. Although we believe
that the expectations reflected in the forward-looking statements
are reasonable, we cannot guarantee that the future results, levels
of activity, performance, or events and circumstances reflected in
the forward-looking statements will be achieved or occur. Moreover,
neither we nor any other person assumes responsibility for the
accuracy and completeness of the forward-looking statements. Such
forward-looking statements relate only to events as of the date of
this press release. We undertake no obligation to update any
forward-looking statements except to the extent required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230724242742/en/
Kiromic BioPharma Linda Phelan Dyson, MPH Global Head,
Corporate Communications ldyson@kiromic.com 281-468-7683
LHA Investor Relations Tirth T. Patel tpatel@lhai.com
212-201-6614
Kiromic BioPharma (NASDAQ:KRBP)
Historical Stock Chart
From Apr 2024 to May 2024
Kiromic BioPharma (NASDAQ:KRBP)
Historical Stock Chart
From May 2023 to May 2024